Biocon gets drug controller’s gesture for CytoSorb gadget to treat basic COVID-19 patients Kumar Jeetendra | May 27, 2020 Biocon on May 27 said its auxiliary Biocon Biologics has gotten the Drugs Controller General of India (DCGI) endorsement for extracorporeal blood refinement (EBP) gadget CytoSorb to diminish ace fiery cytokines levels in affirmed COVID-19 patients admitted to the emergency unit with affirmed or inescapable respiratory disappointment. Biocon Biologics has been conceded the permit for …
Biocon tranquilize gets DCGI gesture for use in moderate to extreme COVID-19 patients Kumar Jeetendra | July 11, 2020 DCGI has vowed to market Itolizumab (ALZUMAb) injection 25mg and 5mL solution for emergency usage within India for the cure of cytokine release syndrome (CRS) at moderate to severe ARDS (acute respiratory distress syndrome) patients thanks to COVID-19, Biocon said in a release. It said Itolizumab is your first publication biologic therapy to become approved …
Biocon’s accomplice Equillium plans Itolizumab’s worldwide clinical preliminary for COVID-19 Kumar Jeetendra | July 13, 2020 Biocon’s partner Equillium has said it is planning to conduct a global randomised controlled clinical trial of Itolizumab in COVID-19 patients, for the American biotech firm will record a US investigational new drug application (IND). Itolizumab, which is used for the treatment of psoriasis, is repurposed for COVID-19, as it regulates the production of inflammatory …
Minitsry of Health rules against incorporating Itolizumab in clinical administration convention for COVID-19 Kumar Jeetendra | July 26, 2020 The National Task Force on COVID-19 has ruled against incorporating Itolizumab medicate in clinical administration conventions for rewarding the malady despite the fact that the DCGI has affirmed its “confined crisis use” in contaminated patients, official sources said. Considering the neglected clinical needs in COVID-19, Itolizumab, a previously endorsed medication of Biocon, utilized for rewarding …
Interview with Dr. Bhavil Kumar Narola, Director – QCA Biocon Sdn. Bhd Kumar Jeetendra | September 11, 2020 Pharma companies are looking for new ways to boost drug discovery potential, reduce time to market and squeeze costs along the whole value chain- Interview with Dr. Bhavil Kumar Narola, Director – QCA Biocon Sdn. Bhd How would you like to summarise your experience in a few lines for our readers? Coaching is the process …
